Arrowhead Pharma (ARWR) Defended at Citi Following ENAC Setback
Tweet Send to a Friend
Citi analyst Mohit Bansal came out to defend Arrowhead Pharma (NASDAQ: ARWR) amid the sharp drop in the stock after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


